PDCD1 and head and neck squamous cell carcinoma: The inhibitors of the programmed cell death 1 (PD-1) receptor nivolumab and pembrolizumab have been approved for treatment of cisplatin-refractory HNSCC and additionally, pembrolizumab has been approved as first-line therapy in patients with locally advanced or metastatic disease [8, 9].